Short‐term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma

Paula, Jayter Silva; Jorge, Rodrigo; Costa, R. A.; Rodrigues, Maria de Lourdes Veronese; Scott, Ingrid U.

doi:10.1111/j.1600-0420.2006.00731.x

Cited by 85 publications

(45 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even though it is only effective for a short period, bevacizumab administration for this purpose yields beneficial results [10,11,22]. In addition, bevacizumab can be used as a combined treatment in patients with NVG who underwent AGV implantation [23].…”

Section: Discussionmentioning

confidence: 99%

“…Shunt surgery owes its success and safety mainly to regression of both iris and angle rubeosis by well-performed PRP [2,9]. However, in cases of eyes with media opacity where an effective PRP could not be performed, this effect, though temporary, can be achieved with anti-VEGF agents [10,11]. Bevacizumab, approved for the treatment of colorectal cancer, is a recombinant antibody against VEGF-A [12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Intravitreal Bevacizumab Injection before Ahmed Glaucoma Valve Implantation in Neovascular Glaucoma

et al. 2013

View full text Add to dashboard Cite

Purpose: To assess the efficacy of preoperative intravitreal bevacizumab injection (IVB) before Ahmed glaucoma valve (AGV) implantation in the treatment of neovascular glaucoma (NVG). Methods: This retrospective, comparative and consecutive case series study included 41 eyes from 41 patients who underwent AGV implantation for treatment of NVG. The study group was composed of 19 patients (19 eyes) to whom IVB was administered before surgery, while the control group was composed of 22 patients (22 eyes) to whom IVB was not administered before AGV implantation. Findings such as intraocular pressures measured before and after surgery, surgical success rates, and postoperative complications were compared between the groups. Results: There were no significant differences in preoperative data between groups. The surgical success rate in the study group (79%) was better than in the control group (64%), but this difference was not statistically significant (p = 0.28). Early postoperative complications such as fibrinous reaction in the anterior chamber as well as hyphema were less frequently observed in the study group. Conclusions: Intravitreal bevacizumab is a useful preparatory step to safely and effectively implant an aqueous shunting tube in eyes with severe NVG and intractable intraocular pressure.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effect of Intravitreal Bevacizumab Injection before Ahmed Glaucoma Valve Implantation in Neovascular Glaucoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Small case series have shown regression of NVI for 4-10 weeks after a single intravitreal injection of bevacizumab. [21][22][23][24][25] While these studies have shown promise for the use of bevacizumab in NVG in the short-term period, an HbA1C of over 7.5%, if the blood sugar was recorded as over 200 units, or if the patient reported widely fl uctuating blood sugars. A designation of uncontrolled hypertension was given if the blood pressure was recorded as over 170 mmHg systolic or over 100 mmHg diastolic on any given chart, or if the patient reported poor control.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal Bevacizumab for Neovascular Glaucoma

Vasudev

Blair

Galasso

et al. 2009

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Purpose: To report 6-month and 1 year outcomes of eyes treated for neovascular glaucoma (NVG) with intravitreal bevacizumab injection and panretinal laser (PRP) compared to those receiving PRP alone. Design: retrospective, consecutive case series. Methods: Charts of patients with NVG from retinal ischemia and at least 6 months of follow-up were reviewed. Patients were treated with one injection of 1.25 mg intravitreal bevacizumab followed by PRP or with PRP alone. The primary outcome was the long-term angle anatomy. Secondary measures included intraocular pressure (IOP), visual acuity, patient compliance, and control of systemic diseases. Results: Fourteen eyes of 12 patients treated with bevacizumab and PRP and 15 eyes of 11 patients treated with PRP alone were included in the study. Mean sectors of open angle at baseline was 1.31 in the bevacizumab group and 1.47 in the retinal ablation group (P = 0.73). Mean sectors of open angle was 2.14 and 1.18 in the bevacizumab and retinal ablation groups, respectively (P < 0.05) at 6-month follow-up, and 2.27 and 1.18, respectively (P < 0.05) at 1-year follow-up. Mean baseline IOP was 32.3 mmHg (±14.8) in the bevacizumab group and 31.8 mmHg (±13) in the PRP group (P = 0.75). At 6-month follow-up, the mean IOP was 18.28 mmHg (±10) in the bevacizumab group and 23.33 mmHg (±14.6) in the PRP group (P = 0.05), and 19.12 mmHg (±6.8) and 26.2 mmHg (±18) (P = 0.1), respectively at 1-year follow-up. Nineteen patients were judged to be noncompliant, 10 had uncontrolled diabetes and 7 had uncontrolled hypertension. Conclusions: This study documents better long-term preservation of open angle and IOP control in eyes receiving bevacizumab along with PRP. We stress that NVG is still associated with poor visual acuity outcomes.

show abstract

“…[17][18][19][20][21] The outcomes of off-label treatment of NVG with intravitreal bevacizumab have been reported. [22][23][24][25][26][27][28][29][30] We have previously published a retrospective interventional case series of NVG eyes describing the natural history of NVG treated with intravitreal bevacizumab. 22 However, conclusions regarding the exact role, efficacy, and drawbacks of intravitreal bevacizumab injection in eyes with NVG could not be drawn, since no comparison to eyes that did not receive this method of treatment was performed.…”

Section: Introductionmentioning

confidence: 99%

Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab

Olmos

Sayed

Moraczewski

et al. 2015

Eye

View full text Add to dashboard Cite

Aims To compare the outcomes of neovascular glaucoma (NVG) treated with and without intravitreal bevacizumab in a large case comparison study. Methods The study is a retrospective, comparative, case series of 163 eyes of 151 patients with NVG, including 99 treated without and 64 treated with intravitreal bevacizumab. Medical and surgical treatments for NVG were assessed. The main outcome measures were visual acuity (VA) and intraocular pressure (IOP).Results At the time of NVG diagnosis, the median VA was count fingers (CF) in the non-bevacizumab group and 2/300 in the bevacizumab group. IOP (mean ± SD) was 43.1 ± 13.0 mm Hg in the non-bevacizumab group and 40.8 ± 11.5 mm Hg in the bevacizumab group. IOP (mean ± SD) decreased to 18.3 ± 13.8 mm Hg in the nonbevacizumab group and 15.3 ± 8.0 mm Hg in the bevacizumab group, and the median VA was CF in both treatment groups at a mean follow-up of 12 months. Panretinal photocoagulation (PRP) substantially reduced the need for glaucoma surgery (Po0.001) in bevacizumab treated NVG eyes. Conclusions Although bevacizumab delayed the need for glaucoma surgery, PRP was the most important factor that reduced the need for surgery. Vision and IOP in eyes with NVG treated with bevacizumab showed no long-term differences when compared with eyes that were not treated with bevacizumab. Thus, intravitreal bevacizumab serves as an effective temporizing treatment, but is not a replacement for close monitoring and definitive treatment of NVG. PRP remains the treatment modality that affects the course of NVG in terms of decreasing the need for surgery to control IOP.

show abstract

Short‐term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma

Cited by 85 publications

References 7 publications

Effect of Intravitreal Bevacizumab Injection before Ahmed Glaucoma Valve Implantation in Neovascular Glaucoma

Effect of Intravitreal Bevacizumab Injection before Ahmed Glaucoma Valve Implantation in Neovascular Glaucoma

Intravitreal Bevacizumab for Neovascular Glaucoma

Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab

Contact Info

Product

Resources

About